First Patient Treated In Study Of Cohera Medical's Sylys™ Surgical Sealant Study to Investigate the Safety of Sylys in Colorectal Procedures
PITTSBURGH, April 23, 2013 /PRNewswire/ -- Cohera Medical, Inc.® (www.coheramedical.com), leading innovator and developer of absorbable surgical adhesives and sealants, today announced the treatment of the first patient in a clinical trial for its latest innovation, Sylys Surgical Sealant, which is designed to reduce leaks in large and small bowel anastomoses. The study, currently underway in Europe, marks a significant milestone in the development of the Company's latest product to revolutionize patient care.
The study, being conducted in two hospitals in the Netherlands, will investigate the safety of Sylys, and its ability to reduce anastomotic leaks following bowel repair. On average, anastomotic leaks occur in 3 - 15% of colorectal procedures and is the cause of one third of the mortalities following colorectal surgery. Sylys has the potential to make an enormous impact on colorectal procedures and has been estimated as a $1 - 4B market.
"We are happy to have successfully treated the first patient in the Sylys study," said Dr. Bemelman of the Academic Medical Center, Amsterdam, in the Netherlands. "We look forward to enrolling more patients in the study and being part of this important research."
"The treatment of this first patient is a major milestone for our company and will be our second class 3 product in humans," said Patrick Daly, President and Chief Executive Officer of Cohera Medical. "Our Sylys product has the potential to transform the healing process following bowel repair and associated complications in colorectal surgeries. We are privileged to work with such a renowned group of doctors who recognize the need for this product on a daily basis."
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.